Funding pharmaceutical businesses

How pharmaceutical businesses typically fund growth

UK pharmaceutical and life-sciences businesses operate on some of the longest development cycles in any sector, and the financing market reflects that. Early-stage drug-development companies are predominantly equity-funded, often through specialist life-sciences venture capital alongside grant funding from Innovate UK, the BBSRC, the MRC, and similar bodies. Debt enters the picture meaningfully at the contract-development-and-manufacturing (CDMO), generic-pharma, distribution, and devices end of the sector, where revenue is established and the asset base can support secured lending.

CDMO and contract-manufacturing businesses raise finance much like other manufacturers, with invoice finance against pharmaceutical-grade customers, asset finance against analytical and production kit, and term lending against the freehold or long-leasehold facility. Specialist life-sciences lenders price these files tightly because the customer base (large pharma, biotech, animal health) has strong covenants and the regulatory barriers to entry support sustained margin.

Generic pharma, OTC, and pharmaceutical distribution are working-capital-intensive. Long stock-holding cycles, regulated batch-release timelines, and extended payment terms from large retailers and wholesalers combine to make a substantial working-capital line a routine requirement. Larger operators in this part of the sector look more like food and beverage businesses in their financing pattern than like research-led pharma.

What lenders look at in pharma files

Regulatory standing is the first filter. MHRA inspections, GMP and GDP certification, FDA standing for export-facing operators, and any open compliance matters all sit above other underwriting criteria. After that, lenders look at customer mix, contract terms with large pharma counterparties, the lifecycle position of key products, and the renewal pipeline.

For CDMO businesses, capacity utilisation and the booking-window on contracted production are the headline metrics. Specialist lenders are comfortable with project-based revenue patterns provided the booking horizon supports the financing tenor. For generics and distribution, the headline metrics are stock turn, working-capital absorption, and the credit picture across the retail and wholesale customer base.

Product overlap

Bedrock places pharmaceutical files into invoice finance for working capital, asset-based lending for businesses combining substantial debtors with batch and finished-goods stock, asset finance for analytical, production, and packaging kit, property finance for laboratory, production, and warehouse facilities, cashflow loans for acquisitions and licensing-deal financing, and equity for businesses past clinical proof-of-concept or revenue-stage operators seeking growth capital.

Worth checking before you apply

The regulatory inspection history is the single most useful piece of context to lead with. A clean GMP record, current MHRA standing, and any recent inspection observations with closed-out actions tell a specialist lender how to size the file before they read the financials. Files that lead with regulatory standing move faster and price better than files that bury it behind a strong P&L.

Specialist debt lenders structure facilities around the clinical-trial calendar, with covenants tied to milestone outcomes. Generalist lenders pricing the same risk without that structure tend to come out wider, even when the headline rate looks competitive.